Regorafenib Hydrochloride

• CAT Number: I005013
• CAS Number: 835621-07-3
• Molecular Formula: C21H16Cl2F4N4O3
• Molecular Weight: 519.28
• Purity: ≥95%
• Target: c-RET
• Solubility: DMSO: ≥ 5.6 mg/mL
• Storage: Store at -20°C
• IUPAC Name: 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide;hydrochloride
• InChI: InChI=1S/C21H15ClF4N4O3.ClH/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26;/h2-10H,1H3,(H,27,31)(H2,29,30,32);1H
• InChIKey: ACSWJKPZXNIVMY-UHFFFAOYSA-N
• SMILES: CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F.Cl

Regorafenib（Cat No.:I005013）, also known as BAY 73-4506, is a multi-target inhibitor that acts on various proteins involved in signaling pathways. It effectively inhibits VEGFR1, VEGFR2, VEGFR3, PDGFRβ, Kit, RET, and Raf-1, with IC50 values of 13 nM, 4.2 nM, 46 nM, 22 nM, 7 nM, 1.5 nM, and 2.5 nM, respectively. By targeting these receptors and enzymes, Regorafenib exhibits potential in cancer treatment by disrupting angiogenesis, cell proliferation, and tumor growth.

Reference

[1]. Wilhelm SM, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer, 2011, 129(1), 245-255.
[2]. Heng DY, et al. Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions. Ther Adv Med Oncol, 2010, 2(1), 39-49.
[3]. Carr BI, et al. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol, 2013, 228(2), 292-297.